Methadon maintenance therapy is one of the substitution therapies needed as an approach to harm reduction or the reduction of the adverse effects of drug abuse. This study aims to fix the infinitive relationship doses with retention of drug dependence patients on methadon maintenance therapies program (PTRM) in Kramat Jati Primary Health Care in 2009-2018. A cross-sectional study is conducted using secondary data from medical records subsequently significance analysis. This research involves 136 patients who were included in the inclusion criteria. Results shown mean initial doses received is 27,65 mg (10-40 mg), after 2 weeks of therapy mean doses received are 51,6 mg (range 22,5 – 85 mg). Average lowest and highest maintenance dose which received is 30,9 mg (range 0,25-115 mg) dan 84,39 mg (range 7,77-126,92 mg). This research shows the retention value 1 year or more reaches 64,71%. Maintenance doses 2 weeks (P=0,005), lowest maintenance doses (P=0,000), average maintenance doses (P=0,004), and history misses doses (P=0,000) have significance with retention. The conclusion that the more optimal maintenance doses received, even more in methadone maintenance therapies. Otherwise, lower missed doses frequency better to patients retention in methadon maintenance therapies.
Breast cancer is a disease of malignant neoplasm which is an abnormal growth of tissue that is different from the surrounding tissue. Various used of chemotherapy in the process of achieving management in cancer that causes the use of benefits and costs. This study aims to determine a more effective therapy in breast cancer patients at RSPAD Gatot Soebroto in 2017. This study was non experimental with comparative study into two group chemotherapy is single group (chemotherapy bondronat) and combination group (chemotherapy doxorubicin-paclitaxel). This study use secondary data from medical records patients on retrospectively. The results showed a decrease in the scale of single chemotherapy (Bondronat) was 82,61% with an average direct medical cost of IDR 9,3 million where as in combination chemotherapy (Doxorubicin-Paclitaxel) 95,65% with an average direct medical cost of IDR 7,6 million. The ACER value in single chemotherapy was IDR 11,3 million and combination chemotherapy was IDR 7,9 million. The ICER value in the two treatment groups was IDR 13,5 million. The conclusion is the combination of chemotherapy of Doxorubicin-Paclitaxel is the most cost-effective than Bondronate single chemotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.